Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Back

ESC Premium Access

Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Session: Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Topic: Pharmacotherapy

Speaker: Doctor H. Contractor (Manchester, GB)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Hussain Contractor

Manchester University Hospitals, Manchester (United Kingdom of Great Britain & Northern Ireland)

0 follower

5 more presentations in this session

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

Speaker: Professor N. Danchin (Paris, FR)

A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial

Speaker: Doctor R. Hein (Munich, DE)

Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI

Speaker: Doctor M. Bertaina (Turin, IT)

Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Speaker: Mrs M. Castineira Busto (Vigo, ES)

The OPTIDUAL trial: long term follow-up

Speaker: Professor G. Helft (Paris, FR)

Access

Abstract

Video

Access the full session

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Speakers: Doctor H. Contractor, Professor N. Danchin, Doctor R. Hein, Doctor M. Bertaina, Mrs M. Castineira Busto...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources